Genetic Risk Factors for Portopulmonary Hypertension in Patients with Advanced Liver Disease

Kari E. Roberts(Tufts Medical Center), Steven M. Kawut(University of Pennsylvania), Neil Kaplowitz(University of Southern California), Evelyn M. Horn(Cornell University), Inga Peter(Icahn School of Medicine at Mount Sinai), David B. Badesch(University of Colorado Denver), Michael B. Fallon(University of Arizona), Hocine Tighiouart(Tufts University), Steven Zacks(University of North Carolina at Chapel Hill), Raymond L. Benza(Allegheny General Hospital), Darren B. Taichman(University of Pennsylvania), Robert S. Brown(Columbia University Irving Medical Center), James F. Trotter(Baylor Scott & White Health), Daniel Rabinowitz(Columbia University), James A. Knowles(Rutgers, The State University of New Jersey), Michael J. Krowka(Mayo Clinic)
American Journal of Respiratory and Critical Care Medicine
February 12, 2009
10.1164/rccm.200809-1472oc
Cited by 232

Related Papers

Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial
|The Lancet|2008|2k
Definitions and Diagnosis of Pulmonary Hypertension
|Journal of the American College of Cardiology|2013|1.8k
Predicting Survival in Pulmonary Arterial Hypertension
|Circulation|2010|1.5k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k